BIOVF (Swedish Orphan Biovitrum AB) Other Current Payables: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOVF Swedish Orphan Biovitrum AB BIOVF
83 GF Score
Price $49.03
GF Value $37.52
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Other Current Payables?

Swedish Orphan Biovitrum AB BIOVF 83 Other Current Payables is $0 Mil as of Jun. 2026. GuruFocus rates BIOVF with a GF Score™ of 83/100 and a GF Value™ of $37.52 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Swedish Orphan Biovitrum AB's Other Current Payables for the quarter that ended in Jun. 2026 was $0 Mil.

Swedish Orphan Biovitrum AB's quarterly Other Current Payables declined from Dec. 2025 ($7 Mil) to Mar. 2026 ($0 Mil) but then stayed the same from Mar. 2026 ($0 Mil) to Jun. 2026 ($0 Mil).

Swedish Orphan Biovitrum AB's annual Other Current Payables declined from Dec. 2023 ($12 Mil) to Dec. 2024 ($8 Mil) and declined from Dec. 2024 ($8 Mil) to Dec. 2025 ($7 Mil).

Swedish Orphan Biovitrum AB Other Current Payables Related Terms

Swedish Orphan Biovitrum AB Other Current Payables Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Other Current Payables Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 11.89 7.83 7.42

Swedish Orphan Biovitrum AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 7.42 0.00 0.00
BIOVF
83GF Score
Swedish Orphan Biovitrum AB BIOVF
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0 Mil mean?
Swedish Orphan Biovitrum AB (BIOVF) has a Other Current Payables of $0 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Other Current Payables too high?
Swedish Orphan Biovitrum AB's current Other Current Payables is $0 Mil. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Other Current Payables compare to ZTS and UTHR?
Swedish Orphan Biovitrum AB's Other Current Payables of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Other Current Payables is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (BIOVF) is currently considered Significantly Overvalued. The stock's GF Value™ is $37.52, compared to a current price of $49.03 — trading 30.7% above its estimated fair value. The current Other Current Payables is $0 Mil. Swedish Orphan Biovitrum AB's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (BIOVF), the current Other Current Payables is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (BIOVF) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of $49.03 is trading 30.7% above its estimated GF Value™ of $37.52. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for BIOVF:

  • Other Current Payables: $0 Mil
  • GF Value™: $37.52 vs. price of $49.03 (30.7% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the BIOVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
83GF Score

Get the complete analysis for BIOVF

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.03
Price
$37.52
GF Value